Premium
Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft
Author(s) -
Tan Gewen,
Kasuya Hideki,
Sahin Tevfik Tolga,
Yamamura Kazuo,
Wu Zhiwen,
Koide Yusuke,
Hotta Yoshihiro,
Shikano Toshio,
Yamada Suguru,
Kanzaki Akiyuki,
Fujii Tsutomu,
Sugimoto Hiroyuki,
Nomoto Shuji,
Nishikawa Yoko,
Tanaka Maki,
Tsurumaru Naoko,
Kuwahara Toshie,
Fukuda Saori,
Ichinose Toru,
Kikumori Toyone,
Takeda Shin,
Nakao Akimasa,
Kodera Yasuhiro
Publication year - 2014
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.29163
Subject(s) - oncolytic virus , bevacizumab , medicine , herpes simplex virus , angiogenesis , combination therapy , breast cancer , cancer research , cancer , oncology , virus , immunology , chemotherapy
Breast cancer is one of the most common and feared cancers faced by women. The prognosis of patients with advanced or recurrent breast cancer remains poor despite refinements in multimodality therapies involving chemotherapeutic and hormonal agents. Multimodal therapy with more specific and effective strategy is urgently needed. The oncolytic herpes simplex virus (HSV) has potential to become a new effective treatment option because of its broad host range and tumor selective viral distribution. Bevacizumab is a monoclonal antibody against VEGFA, which inhibits angiogenesis and therefore tumor growth. Our approach to enhance the antitumor effect of the oncolytic HSV is to combine oncolytic HSV HF10 and bevacizumab in the treatment of breast cancer. Our results showed that bevacizumab enhanced viral distribution as well as tumor hypoxia and expanded the population of apoptotic cells and therefore induced a synergistic antitumor effect. HF10 is expected to be a promising agent in combination with bevacizumab in the anticancer treatment.